Effective intravenous delivery of adenovirus armed with TNFα and IL-2 improves anti-PD-1 checkpoint blockade in non-small cell lung cancer

References

• Shinohara S, Takahashi Y, Komuro H, Matsui T, Sugita Y, Demachi-Okamura A, Muraoka D, Takahara H, Nakada T, Sakakura N, et al. New evaluation of the tumor immune microenvironment of non-small cell lung cancer and its association with prognosis. J Immunother Cancer. 2022 Apr;10(4):e003765. doi:10.1136/jitc-2021-003765.
   PubMed Web of Science ®Google Scholar
• Chang YS, Tu SJ, Chen YC, Liu TY, Lee YT, Yen JC, Fang HY, Chang JG. Mutation profile of non-small cell lung cancer revealed by next generation sequencing. Respir Res. 2021 Jan 6;22(1):3. doi:10.1186/s12931-020-01608-5.
   PubMed Web of Science ®Google Scholar
• Mithoowani H, Febbraro M. Non-small-cell lung cancer in 2022: A review for general practitioners in oncology. Curr Oncol. 2022 Mar 9;29(3):1828–14. doi:10.3390/curroncol29030150.
   PubMed Web of Science ®Google Scholar
• Reck M, Ciuleanu TE, Lee JS, Schenker M, Audigier-Valette C, Zurawski B, Linardou H, Otterson GA, Salman P, Nishio M, et al. First-line nivolumab plus ipilimumab versus chemotherapy in advanced NSCLC with 1% or greater tumor PD-L1 expression: Patient-reported outcomes from CheckMate 227 part 1. J Thorac Oncol. 2021 Apr;16(4):665–676. doi:10.1016/j.jtho.2020.12.019.
   PubMed Web of Science ®Google Scholar
• Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson SJ, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022 May 26;386(21):1973–1985. doi:10.1056/NEJMoa2202170.
   PubMed Web of Science ®Google Scholar
• Maione P, Sacco PC, Sgambato A, Casaluce F, Rossi A, Gridelli C. Overcoming resistance to targeted therapies in NSCLC: current approaches and clinical application. Ther Adv Med Oncol. 2015 Sep;7(5):263–273. doi:10.1177/1758834015595048.
   PubMed Web of Science ®Google Scholar
• Jenkins RW, Barbie DA, Flaherty KT. Mechanisms of resistance to immune checkpoint inhibitors. Br J Cancer. 2018 Jan;118(1):9–16. doi:10.1038/bjc.2017.434.
   PubMed Web of Science ®Google Scholar
• Li Z, Feiyue Z, Gaofeng L, Haifeng L. Lung cancer and oncolytic virotherapy–enemy’s enemy. Transl Oncol. 2023 Jan;27:101563. doi:10.1016/j.tranon.2022.101563.
   PubMed Web of Science ®Google Scholar
• Havunen R, Siurala M, Sorsa S, Grönberg-Vähä-Koskela S, Behr M, Tähtinen S, Santos JM, Karell P, Rusanen J, Nettelbeck DM, et al. Oncolytic adenoviruses armed with tumor necrosis factor alpha and interleukin-2 enable successful adoptive cell therapy. Mol Ther Oncolytics. 2016 Dec 31;4:77–86. doi:10.1016/j.omto.2016.12.004.
   PubMed Web of Science ®Google Scholar
• Small EJ, Carducci MA, Burke JM, Rodriguez R, Fong L, van Ummersen L, Yu DC, Aimi J, Ando D, Working P, et al. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther. 2006 Jul;14(1):107–117. doi:10.1016/j.ymthe.2006.02.011.
   PubMed Web of Science ®Google Scholar
• García M, Moreno R, Gil-Martin M, Cascallò M, de Olza MO, Cuadra C, Piulats JM, Navarro V, Domenech M, Alemany R, et al. A phase 1 trial of oncolytic adenovirus ICOVIR-5 administered intravenously to cutaneous and uveal melanoma patients. Hum Gene Ther. 2019 Mar;30(3):352–364. doi:10.1089/hum.2018.107.
   PubMed Web of Science ®Google Scholar
• Bottermann M, Foss S, van Tienen LM, Vaysburd M, Cruickshank J, O’Connell K, Clark J, Mayes K, Higginson K, Hirst JC, et al. TRIM21 mediates antibody inhibition of adenovirus-based gene delivery and vaccination. Proc Natl Acad Sci U S A. 2018 Oct 9;115(41):10440–10445. doi:10.1073/pnas.1806314115.
   PubMed Web of Science ®Google Scholar
• Bottermann M, Foss S, Caddy SL, Clift D, van Tienen LM, Vaysburd M, Cruickshank J, O’Connell K, Clark J, Mayes K, et al. Complement C4 prevents viral infection through capsid inactivation. Cell Host & Microbe. 2019 Apr 10;25(4):617–629.e7. doi:10.1016/j.chom.2019.02.016.
   PubMed Web of Science ®Google Scholar
• Zheng M, Huang J, Tong A, Yang H. Oncolytic viruses for cancer therapy: Barriers and Recent Advances. Mol Ther Oncolytics. 2019 Nov 2;15:234–247. doi:10.1016/j.omto.2019.10.007.
   PubMed Web of Science ®Google Scholar
• Shayan S, Arashkia A, Azadmanesh K. Modifying oncolytic virotherapy to overcome the barrier of the hypoxic tumor microenvironment. Where do we stand? Cancer Cell Int. 2022 Nov 24;22(1):370. doi:10.1186/s12935-022-02774-w.
   PubMed Web of Science ®Google Scholar
• Xie R, Bi X, Shang B, Zhou A, Shi H, Shou J. Efficacy and safety of oncolytic viruses in advanced or metastatic cancer: a network meta-analysis. Virol J. 2021 Jul 31;18(1):158. doi:10.1186/s12985-021-01630-z.
   PubMed Web of Science ®Google Scholar
• Santos JM, Heiniö C, Cervera-Carrascon V, Quixabeira DCA, Siurala M, Havunen R, Butzow R, Zafar S, de Gruijl T, Lassus H, et al. Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity. J Immunother Cancer. 2020 Jan;8(1):e000188. doi:10.1136/jitc-2019-000188.
   PubMed Web of Science ®Google Scholar
• Cervera-Carrascon V, Siurala M, Santos JM, Havunen R, Tähtinen S, Karell P, Sorsa S, Kanerva A, Hemminki A. TNFα and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade. Oncoimmunology. 2018 Apr 9;7(5):e1412902. doi:10.1080/2162402X.2017.1412902.
   PubMed Web of Science ®Google Scholar
• Clubb JHA, Kudling TV, Heiniö C, Basnet S, Pakola S, Cervera Carrascón V, Santos JM, Quixabeira DCA, Havunen R, Sorsa S, et al. Adenovirus encoding tumor necrosis factor alpha and interleukin 2 induces a tertiary lymphoid structure signature in immune checkpoint inhibitor refractory head and neck cancer. Front Immunol. 2022 Mar 7;13:794251. doi:10.3389/fimmu.2022.794251.
   PubMed Web of Science ®Google Scholar
• Heiniö C, Clubb J, Kudling T, Quixabeira D, Cervera-Carrascon V, Havunen R, Grönberg-Vähä-Koskela S, Santos JM, Tapper J, Kanerva A, et al. Effective combination immunotherapy with oncolytic adenovirus and anti-PD-1 for treatment of human and murine ovarian cancers. Diseases. 2022 Aug 8;10(3):52. doi:10.3390/diseases10030052.
   PubMedGoogle Scholar
• Havunen R, Santos JM, Sorsa S, Rantapero T, Lumen D, Siurala M, Airaksinen AJ, Cervera-Carrascon V, Tähtinen S, Kanerva A, et al. Abscopal effect in non-injected tumors achieved with cytokine-armed oncolytic adenovirus. Mol Ther Oncolytics. 2018 Nov 6;11:109–121. doi:10.1016/j.omto.2018.10.005.
   PubMed Web of Science ®Google Scholar
• Siurala M, Havunen R, Saha D, Lumen D, Airaksinen AJ, Tähtinen S, Cervera-Carrascon V, Bramante S, Parviainen S, Vähä-Koskela M, et al. Adenoviral delivery of tumor necrosis factor-α and interleukin-2 enables successful adoptive cell therapy of immunosuppressive melanoma. Mol Ther. 2016 Aug;24(8):1435–1443. doi:10.1038/mt.2016.137.
   PubMed Web of Science ®Google Scholar
• Kanerva A, Mikheeva GV, Krasnykh V, Coolidge CJ, Lam JT, Mahasreshti PJ, Barker SD, Straughn M, Barnes MN, Alvarez RD, et al. Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin Cancer Res. 2002 Jan;8(1):275–280.
   PubMed Web of Science ®Google Scholar
• Coudray-Meunier C, Fraisse A, Martin-Latil S, Guillier L, Perelle S. Discrimination of infectious hepatitis a virus and rotavirus by combining dyes and surfactants with RT-Qpcr. BMC Microbiol. 2013 Oct 1;13:216. doi:10.1186/1471-2180-13-216.
   PubMed Web of Science ®Google Scholar
• Leifels M, Cheng D, Sozzi E, Shoults DC, Wuertz S, Mongkolsuk S, Sirikanchana K. Capsid integrity quantitative PCR to determine virus infectivity in environmental and food applications – a systematic review. Water Research X. 2021;11:100080. doi:10.1016/j.wroa.2020.100080.
   PubMed Web of Science ®Google Scholar
• Kohanbash G, McKaveney K, Sakaki M, Ueda R, Mintz AH, Amankulor N, Fujita M, Ohlfest JR, Okada H. GM-CSF promotes the immunosuppressive activity of glioma-infiltrating myeloid cells through interleukin-4 receptor-α. Cancer Res. 2013 Nov 1;73(21):6413–6423. doi:10.1158/0008-5472.CAN-12-4124.
   PubMed Web of Science ®Google Scholar
• Hong IS. Stimulatory versus suppressive effects of GM-CSF on tumor progression in multiple cancer types. Experimental & Molecular Medicine. 2016 Jul 1;48(7):e242. doi:10.1038/emm.2016.64.
   PubMedGoogle Scholar
• Tähtinen S, Kaikkonen S, Merisalo-Soikkeli M, Grönberg-Vähä-Koskela S, Kanerva A, Parviainen S, Vähä-Koskela M, Hemminki A, Shiku H. Favorable alteration of tumor microenvironment by immunomodulatory cytokines for efficient T-cell therapy in solid tumors. PLoS One. 2015 Jun 24;10(6):e0131242. doi:10.1371/journal.pone.0131242.
   PubMed Web of Science ®Google Scholar
• Baumeister SH, Freeman GJ, Dranoff G, Sharpe AH. Coinhibitory Pathways in Immunotherapy for Cancer. Annu Rev Immunol. 2016;34(1):539–573. doi:10.1146/annurev-immunol-032414-112049.
   PubMed Web of Science ®Google Scholar
• Fushimi T, Kojima A, Moore MA, Crystal RG. Macrophage inflammatory protein 3alpha transgene attracts dendritic cells to established murine tumors and suppresses tumor growth. J Clin Invest. 2000 May;105(10):1383–1393. doi:10.1172/JCI7548.
   PubMed Web of Science ®Google Scholar
• Kikuchi T, Crystal RG. Anti-tumor immunity induced by in vivo adenovirus vector-mediated expression of CD40 ligand in tumor cells. Hum Gene Ther. 1999 May 20;10(8):1375–1387. doi:10.1089/10430349950018049.
   PubMed Web of Science ®Google Scholar
• Hollern DP, Xu N, Thennavan A, Glodowski C, Garcia-Recio S, Mott KR, He X, Garay JP, Carey-Ewend K, Marron D, et al. B cells and T follicular helper cells mediate response to checkpoint inhibitors in high mutation burden mouse models of breast cancer. Cell. 2019 Nov 14;179(5):1191–1206.e21. doi:10.1016/j.cell.2019.10.028.
   PubMed Web of Science ®Google Scholar
• Petitprez F, de Reyniès A, Keung EZ, Chen TW, Sun CM, Calderaro J, Jeng YM, Hsiao LP, Lacroix L, Bougoüin A, et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature. 2020 Jan;577(7791):556–560. doi:10.1038/s41586-019-1906-8.
   PubMed Web of Science ®Google Scholar
• Xu Z, Tian J, Smith JS, Byrnes AP. Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, and complement. J Virol. 2008 Dec;82(23):11705–11713. doi:10.1128/JVI.01320-08.
   PubMed Web of Science ®Google Scholar
• Zafar S, Quixabeira DCA, Kudling TV, Cervera-Carrascon V, Santos JM, Grönberg-Vähä-Koskela S, Zhao F, Aronen P, Heiniö C, Havunen R, et al. Ad5/3 is able to avoid neutralization by binding to erythrocytes and lymphocytes. Cancer Gene Ther. 2021 May;28(5):442–454. doi:10.1038/s41417-020-00226-z.
   PubMed Web of Science ®Google Scholar
• Hamilton G, Plangger A. The impact of NK cell-based therapeutics for the treatment of lung cancer for biologics: Targets and therapy. Biologics. 2021 Jul 7;15:265–277. doi:10.2147/BTT.S290305.
   PubMedGoogle Scholar
• Casanova-Acebes M, Dalla E, Leader AM, LeBerichel J, Nikolic J, Morales BM, Brown M, Chang C, Troncoso L, Chen ST, et al. Tissue-resident macrophages provide a pro-tumorigenic niche to early NSCLC cells. Nature. 2021 Jul;595(7868):578–584. doi:10.1038/s41586-021-03651-8.
   PubMed Web of Science ®Google Scholar
• Zhang J, Rousseaux N, Walzer T. Eomes and T-bet, a dynamic duo regulating NK cell differentiation. Bioessays. 2022 Mar;44(3):e2100281. doi:10.1002/bies.202100281.
   PubMed Web of Science ®Google Scholar
• Gill S, Vasey AE, De Souza A, Baker J, Smith AT, Kohrt HE, Florek M, Gibbs KD Jr, Tate K, Ritchie DS, et al. Rapid development of exhaustion and down-regulation of eomesodermin limit the anti-tumor activity of adoptively transferred murine natural killer cells. Blood. 2012 Jun 14;119(24):5758–5768. doi:10.1182/blood-2012-03-415364.
   PubMed Web of Science ®Google Scholar
• Huang C, Bi J. Expression regulation and function of T-Bet in NK cells. Front Immunol. 2021 Oct 5;12:761920. doi:10.3389/fimmu.2021.761920.
   PubMedGoogle Scholar
• Niu C, Li M, Zhu S, Chen Y, Zhou L, Xu D, Xu J, Li Z, Li W, Cui J. PD-1-positive natural killer cells have a weaker anti-tumor function than that of PD-1-negative natural killer cells in lung cancer. Int J Med Sci. 2020 Jul 19;17(13):1964–1973. doi:10.7150/ijms.47701.
   PubMed Web of Science ®Google Scholar
• Qiao DR, Cheng JY, Yan WQ, Li HJ. PD-L1/PD-1 blockage enhanced the cytotoxicity of natural killer cell on the non-small cell lung cancer (NSCLC) by granzyme B secretion. Clin Transl Oncol. 2023 Mar 1;25(8):2373–2383. doi:10.1007/s12094-023-03120-w.
   PubMed Web of Science ®Google Scholar
• Zalfa C, Paust S. Natural killer cell interactions with myeloid derived suppressor cells in the tumor microenvironment and implications for cancer immunotherapy. Front Immunol. 2021 May 5;12:633205. doi:10.3389/fimmu.2021.633205.
   PubMed Web of Science ®Google Scholar
• Wang JB, Huang X, Li FR. Impaired dendritic cell functions in lung cancer: a review of recent advances and future perspectives. Cancer Commun (Lond). 2019 Jul 15;39(1):43. doi:10.1186/s40880-019-0387-3.
   PubMedGoogle Scholar
• Russo E, Laffranchi M, Tomaipitinca L, Del Prete A, Santoni A, Sozzani S, Bernardini G. NK cell anti-tumor surveillance in a myeloid cell-shaped environment. Front Immunol. 2021 Dec 17;12:787116. doi:10.3389/fimmu.2021.787116.
   PubMed Web of Science ®Google Scholar
• Paschall AV, Zhang R, Qi CF, Bardhan K, Peng L, Lu G, Yang J, Merad M, McGaha T, Zhou G, et al. IFN regulatory factor 8 represses GM-CSF expression in T cells to affect myeloid cell lineage differentiation. The Journal Of Immunology query. 2015 Mar 1;194(5):2369–2379. doi:10.4049/jimmunol.1402412.
   PubMed Web of Science ®Google Scholar
• Li HY, McSharry M, Bullock B, Nguyen TT, Kwak J, Poczobutt JM, Sippel TR, Heasley LE, Weiser-Evans MC, Clambey ET, et al. The tumor microenvironment regulates sensitivity of murine lung tumors to PD-1/PD-L1 antibody blockade. Cancer Immunol Res. 2017 Sep;5(9):767–777. doi:10.1158/2326-6066.CIR-16-0365.
   PubMed Web of Science ®Google Scholar
• Li S, Simoni Y, Zhuang S, Gabel A, Ma S, Chee J, Islas L, Cessna A, Creaney J, Bradley RK, et al. Characterization of neoantigen-specific T cells in cancer resistant to immune checkpoint therapies. Proc Natl Acad Sci U S A. 2021 Jul 27;118(30):e2025570118. doi:10.1073/pnas.2025570118.
   PubMed Web of Science ®Google Scholar